南京醫藥(600713.SH):南京醫藥集團無償劃轉23.22%股權至南京新工集團
格隆匯6月23日丨南京醫藥(600713.SH)公吿,公司於2021年6月23日收到南京新工集團的通知,南京新工集團以2020年12月31日為基準日,以無償劃轉的方式受讓公司控股股東南京醫藥集團有限責任公司(“南京醫藥集團”)所持有的公司約2.4181億股流通股股份,佔公司總股本23.22%。
2021年6月23日,南京新工集團與南京醫藥集團簽署《國有股份無償劃轉協議》。此次國有股權無償劃轉完成後,南京新工集團持有公司約3.2745億股流通股股份,佔公司總股本的31.44%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.